- Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Hong, D.S., Sebti, S.M., Newman, R.A., Blaskovich, M.A., Ye, L., Gagel, R.F., Moulder, S., Wheler, J.J., Naing, A., Tannir, N.M., Ng, C.S., Sherman, S.I., El Naggar, A.K., Khan, R., Trent, J., Wright, J.J., Kurzrock, R. Clin. Cancer Res. (2009)